A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Study Identifier:
ALXN2040-GA-201
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
Aug 2021 - Jul 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 60+ years
Requirements Information
Sex
Female & Male
Age
60+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
Aug 2021 - Jul 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 60+ years years
Requirements Information
Protocol Summary
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
Trial Locations
Location
Status
Location
Research Site
Phoenix, Arizona, United States, 85020
Status
N/A
Location
Research Site
Beverly Hills, California, United States, 90211
Status
N/A
Location
Research Site
Encino, California, United States, 91436
Status
N/A
Location
Research Site
Fresno, California, United States, 93720
Status
N/A
Location
Research Site
Fullerton, California, United States, 92835
Status
N/A
Location
Research Site
La Jolla, California, United States, 92093
Status
N/A